Literature DB >> 31022059

Eye immune privilege? Nivolumab plus ipilimumab: successful treatment in a patient with cutaneous melanoma and ocular metastases.

Amaya B Fernandez-Diaz1, Adrian García-Medina2, Blanca Ferrer-Guillen3, Alfonso Berrocal1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31022059     DOI： 10.1097/CMR.0000000000000591

Source DB:  PubMed          Journal:  Melanoma Res        ISSN： 0960-8931            Impact factor:   3.599


× No keyword cloud information.
  2 in total

1.  Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading.

Authors:  Jasmine H Francis; Duncan Berry; David H Abramson; Christopher A Barker; Chris Bergstrom; Hakan Demirci; Michael Engelbert; Hans Grossniklaus; Baker Hubbard; Codrin E Iacob; Korey Jaben; Madhavi Kurli; Michael A Postow; Jedd D Wolchok; Ivana K Kim; Jill R Wells
Journal:  Ophthalmology       Date:  2019-09-24       Impact factor: 12.079

2.  Dinutuximab Synergistically Enhances the Cytotoxicity of Natural Killer Cells to Retinoblastoma Through the Perforin-Granzyme B Pathway.

Authors:  Huixue Wang; Jie Yang; Hui Pan; Mei Chee Tai; Mohamed H Maher; Renbing Jia; Shengfang Ge; Linna Lu
Journal:  Onco Targets Ther       Date:  2020-05-08       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.